Frontera Therapeutics is an AAV gene therapy company that focuses on rAAV therapies for the global market.
Frontera Therapeutics has raised $160.0M in total funding. The most recent round was Series B. The last funding was announced in June 2022.
Frontera Therapeutics's investors include HSG, OrbiMed, Loyal Valley Capital, Boyu Capital, Creacion Ventures.
Frontera Therapeutics is headquartered in Bedford, United States.
Frontera Therapeutics is an AAV gene therapy company that focuses on rAAV therapies for the global market.
Frontera Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Frontera Therapeutics — Funding & Investors." VCBacked, June 24, 2022, https://www.vcbacked.co/company/frontera-therapeutics. Accessed September 29, 2026.
VCBacked. (2022). Frontera Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/frontera-therapeutics
{{cite web |title=Frontera Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/frontera-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated